Global Information
회사소개 | 문의 | 비교리스트

자궁내막증 : 파이프라인 리뷰

Endometriosis - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 232822
페이지 정보 영문 148 Pages
가격
US $ 2,000 ₩ 2,402,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,804,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,206,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


자궁내막증 : 파이프라인 리뷰 Endometriosis - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 148 Pages

자궁내막증이란 통상은 자궁 내부에 있는 조자궁내막증이란 일반적으로 자궁 내부에 있는 조직(자궁내막)이 자궁 외부에까지 확대되는(자궁내막증식) 질환으로 자주 통증을 수반합니다. 주요 증상으로 골반통, 월경 경련, 염증, 불임증, 이상 출혈 등을 들 수 있습니다. 질병 소질에는 배뇨 불순과 골반내 감염증 병력, 가족력 등이 포함됩니다. 주요 치료제에는 비스테로이드계 항염증성 약물(NSAID), 경구 피임약, 황체 호르몬 물질 등이 있습니다.

세계 각국에서의 자궁내막증(Endometriosis) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발 및 출시 최신 동향, 임상시험 각 단계별 제품 목록, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

서론

  • 조사 범위

자궁내막증 개요

치료제 개발

  • 파이프라인 제품 개요
  • 파이프라인 제품 비교 분석

자궁내막증 : 기업에서 개발중인 치료제

자궁내막증 : 대학/기관에서 연구중인 치료제

자궁내막증 : 파이프라인 제품 상황 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품
  • 개발 단계가 불명확한 제품

자궁내막증 : 기업에서 개발중인 제품

자궁내막증 : 대학/기관에서 연구중인 제품

자궁내막증 치료제 개발에 참여하고 있는 기업

  • AbbVie Inc.
  • Addex Therapeutics Ltd
  • APAvadis Biotechnologies Srl
  • Astellas Pharma Inc.
  • Bayer AG
  • Dongkook Pharmaceutical Co., Ltd.
  • ElexoPharm GmbH
  • EndoCeutics, Inc.
  • Euroscreen S.A.
  • Evotec AG
  • Forendo Pharma Limited
  • GlaxoSmithKline Plc
  • Kissei Pharmaceutical Co., Ltd.
  • Lipicard Technologies Limited
  • Nippon Shinyaku Co., Ltd.
  • Orphagen Pharmaceuticals, Inc.
  • Philogen S.p.A.
  • Repros Therapeutics Inc.
  • SK Chemicals Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • ValiRx Plc

자궁내막증 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 병용요법 제품(Combination Products)별
  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

약제 프로파일

자궁내막증 : 최근의 파이프라인 동향

자궁내막증 : 휴지 상태인 프로젝트

자궁내막증 : 개발이 중지된 제품

자궁내막증 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

LSH 16.10.07

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Endometriosis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Endometriosis - Pipeline by Adynxx Inc, H1 2020
  • Endometriosis - Pipeline by Aptorum Group Ltd, H1 2020
  • Endometriosis - Pipeline by ARTham Therapeutics Inc, H1 2020
  • Endometriosis - Pipeline by Auritec Pharmaceuticals Inc, H1 2020
  • Endometriosis - Pipeline by Bayer AG, H1 2020
  • Endometriosis - Pipeline by Bol Pharma, H1 2020
  • Endometriosis - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020
  • Endometriosis - Pipeline by Context Therapeutics LLC, H1 2020
  • Endometriosis - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2020
  • Endometriosis - Pipeline by ElexoPharm GmbH, H1 2020
  • Endometriosis - Pipeline by Enteris BioPharma Inc, H1 2020
  • Endometriosis - Pipeline by Eurofarma Laboratorios SA, H1 2020
  • Endometriosis - Pipeline by Evestra Inc, H1 2020
  • Endometriosis - Pipeline by Evotec SE, H1 2020
  • Endometriosis - Pipeline by FemmePharma Global Healthcare Inc, H1 2020
  • Endometriosis - Pipeline by Forendo Pharma Oy, H1 2020
  • Endometriosis - Pipeline by GeneScience Pharmaceuticals Co Ltd, H1 2020
  • Endometriosis - Pipeline by Immunitor Inc, H1 2020
  • Endometriosis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
  • Endometriosis - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2020
  • Endometriosis - Pipeline by Livzon Pharmaceutical Group Co Ltd, H1 2020
  • Endometriosis - Pipeline by Luye Pharma Group Ltd, H1 2020
  • Endometriosis - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2020
  • Endometriosis - Pipeline by Navad Life Sciences Pte Ltd, H1 2020
  • Endometriosis - Pipeline by Nippon Shinyaku Co Ltd, H1 2020
  • Endometriosis - Pipeline by Philogen SpA, H1 2020
  • Endometriosis - Pipeline by Predictive Therapeutics LLC, H1 2020
  • Endometriosis - Pipeline by PregLem SA, H1 2020
  • Endometriosis - Pipeline by SYNG Pharmaceuticals Inc, H1 2020
  • Endometriosis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Endometriosis - Pipeline by Temple Therapeutics BV, H1 2020
  • Endometriosis - Pipeline by TiumBio Co Ltd, H1 2020
  • Endometriosis - Pipeline by Union Therapeutics AS, H1 2020
  • Endometriosis - Pipeline by ValiRx Plc, H1 2020
  • Endometriosis - Pipeline by Viramal Ltd, H1 2020
  • Endometriosis - Pipeline by Xbrane Biopharma AB, H1 2020
  • Endometriosis - Dormant Projects, H1 2020
  • Endometriosis - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Endometriosis - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Endometriosis - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Endometriosis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis - Pipeline Review, H1 2020, provides an overview of the Endometriosis (Women's Health) pipeline landscape.

Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. Risk factors age, uterine abnormalities, history of pelvic infection and family history. Treatment includes NSAIDs, birth control pills and progestins.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometriosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Endometriosis (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometriosis (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 11, 12, 1, 16, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 2 molecules, respectively.

Endometriosis (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Endometriosis (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Endometriosis (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Endometriosis (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Endometriosis (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Endometriosis (Women's Health)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Endometriosis (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Endometriosis (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Endometriosis - Overview
  • Endometriosis - Therapeutics Development
  • Endometriosis - Therapeutics Assessment
  • Endometriosis - Companies Involved in Therapeutics Development
  • Endometriosis - Drug Profiles
  • Endometriosis - Dormant Projects
  • Endometriosis - Discontinued Products
  • Endometriosis - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q